OncoMatch/Clinical Trials/NCT06224855
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
Is NCT06224855 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies DXC006 for advanced solid tumors.
Treatment: DXC006 — This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC006 in patients with a variety of solid tumors, including small cell lung cancer, multiple myeloma, and neuroblastoma, and hematological malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Disease stage
Metastatic disease required
Patients with solid tumors or hematologic tumors who have failed standard therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: standard therapy
Patients with solid tumors or hematologic tumors who have failed standard therapy
Cannot have received: systemic anti-myeloma therapy
Patients have received systemic anti-myeloma therapy or investigational drug therapy within 28 days or 5 half-lives (whichever is shorter) prior to the first dose
Cannot have received: investigational drug therapy
Patients have received systemic anti-myeloma therapy or investigational drug therapy within 28 days or 5 half-lives (whichever is shorter) prior to the first dose
Cannot have received: radiation therapy
Radiotherapy within 14 days prior to the first dose
Cannot have received: monoclonal antibody
Patients have received monoclonal antibody therapy within 30 days before the first dose
Cannot have received: autologous hematopoietic stem cell transplantation
Patients have received autologous hematopoietic stem cell transplantation within 100 days before the first dose
Cannot have received: allogeneic hematopoietic stem cell transplantation
Patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT)
Cannot have received: solid organ transplantation
history of solid organ transplantation
Cannot have received: same targeted therapy (phase Ia only)
Patients have received the same targeted therapy in the past (limited to phase Ia clinical trials)
Cannot have received: plasmapheresis
Within 14 days before the first dose: received plasmapheresis
Cannot have received: systemic corticosteroids >10 mg prednisone equivalent >3 days
Exception: short-term use for prevention of contrast allergy can be enrolled
Treatment with > 10 mg of prednisone or equivalent doses of systemic corticosteroids per day for more than 3 consecutive days (short-term use for the prevention of contrast allergy can be enrolled)
Cannot have received: live attenuated vaccine
Received live attenuated vaccine within 28 days before the first dose
Lab requirements
Blood counts
multiple myeloma: ANC ≥ 1.0×10^9/L (G-CSF allowed, not within 7 days of labs); platelets ≥ 50×10^9/L (no platelet transfusion within 7 days of labs); HGB ≥ 75 g/L (RBC transfusion/erythropoietin allowed, no RBC transfusion within 7 days of labs). Other patients: ANC ≥ 1.5×10^9/L, platelets ≥ 100×10^9/L, HGB ≥ 90 g/L
Kidney function
creatinine clearance (Ccr) ≥ 30mL/min in patients with multiple myeloma, Creatinine ≤ 1.5×ULN in other patients
Liver function
total bilirubin (TBIL) ≤ 1.5×ULN, except for subjects with congenital bilirubinemia, such as Gilbert's syndrome (direct bilirubin ≤ 1.5×ULN); AST and ALT ≤ 3.0×ULN; with liver metastases, AST and ALT ≤ 5× ULN
Cardiac function
LVEF ≥ 50%
Organ function must meet the following requirements: ... see full criteria for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify